Pharmacokinetic studies of lanoteplase, a novel tissue plasminogen activator (1) plasma levels after a single bolus intravenous administration in rats, rabbits and dogs

Pharmacometrics

Volumn 53, Issue 1, 1997, Pages 1-10

  Hata, Kimiyo ^a   Komoriya, Kazumi ^a   Takada, Naomi ^a   Kobayashi, Hayao ^a   Ohnuma, Norio ^a   Hayashi, Yujiro ^a  

^a SUNTORY LTD   (Japan)

Author keywords

(rat, rabbit and dog); Elimination half life; Lanoteplase; Liver; Novel tissue plasminogen activator; Pharmacokinetics; Total body clearance

Indexed keywords

ALTEPLASE; LANOTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER FAILURE; MALE; NONHUMAN; PHARMACOKINETICS; RABBIT; RAT;

EID: 0030992944     PISSN: 03008533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Camani, C. and Kruithof, E.K.O. (1994): Clearance receptors for tissue-type plasminogen activator, Intl J. Hematology, 60, 97-109.
2. Emeis, J.J., Hoogen, C.M. and Jense, D. (1985): Hepatic clearance of tissue-type plasminogen activator in rats, Thromb. Hematostas., 54, 661-664.
3. (1997) Plasminogen Activator, LanoteplaseOftftIOffi (2) 53, 11-21.
4. Martin, U., Sponer, G. and Strein, K. (1993): Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats, Drug Metab. Dispos., 21, 236-241.
5. Miyachi, Y., Vitukaitis, J.L., Nieschlag, E. and Lipset, M.B. (1972): Enzymatic radioiodination of gonadotropins, J. Clin. Endocrinol. Metab., 34, 23-28.
6. Mohler, M.A., Refino, C.J., Chen, S.A., Chen, A.B. and Hotchkiss, A.J. (1986): D-Phe-Pro-Arg-chloromethyl ketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy, Thromb. Hematostas., 56, 160-164.
7. Verstraete, M., Bounameaux, H., Cock, F., Werf, F.V. and Collen, D. (1985): Pharmacokinetics and systemic Fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans, J. Pharmacol. Exp. Ther., 235, 505-512.